


# Identification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies

Vijay M. Shahani,<sup>†,‡,§</sup> Peibin Yue,<sup>§,||</sup> Sina Haftchenary,<sup>†,‡</sup> Wei Zhao,<sup>||</sup> Julie L. Lukkarila,<sup>†,‡</sup> Xiaolei Zhang,<sup>||</sup> Daniel Ball,<sup>‡</sup> Christina Nona,<sup>‡</sup> Patrick T. Gunning,<sup>\*,†,‡</sup> and James Turkson<sup>\*,||</sup>

Departments of <sup>†</sup>Chemistry, and <sup>‡</sup>Chemical and Physical Sciences, University of Toronto, 3359 Mississauga Road North, Mississauga, ON, L5L 1C6, Canada, and <sup>||</sup>Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, 6900 Lake Nona Boulevard, Orlando, Florida 32827, United States

**ABSTRACT** To facilitate the discovery of clinically useful Stat3 inhibitors, computational analysis of the binding to Stat3 of the existing Stat3 dimerization disruptors and quantitative structure–activity relationships (QSAR) were pursued, by which a pharmacophore model was derived for predicting optimized Stat3 dimerization inhibitors. The 2,6,9-trisubstituted-purine scaffold was functionalized in order to access the three subpockets of the Stat3 SH2 domain surface and to derive potent Stat3-binding inhibitors. Select purine scaffolds showed good affinities ( $K_D$ , 0.8–12  $\mu\text{M}$ ) for purified, nonphosphorylated Stat3 and inhibited Stat3 DNA-binding activity *in vitro* and intracellular phosphorylation at 20–60  $\mu\text{M}$ . Furthermore, agents selectively suppressed viability of human prostate, breast and pancreatic cancer cells, and v-Src-transformed mouse fibroblasts that harbor aberrant Stat3 activity. Studies herein identified novel small-molecule trisubstituted purines as effective inhibitors of constitutively active Stat3 and of the viability of Stat3-dependent tumor cells, and are the first to validate the use of purine bases as templates for building novel Stat3 inhibitors.

**KEYWORDS** Stat3, small-molecule inhibitors, molecular modeling, 3D-QSAR pharmacophore model, purine scaffold, cell viability, antitumor cell effects



The signal transducer and activator of transcription (STAT) family of proteins are cytoplasmic transcription factors with important roles in mediating cellular responses, including cell growth and differentiation, and inflammation and immune responses.<sup>1</sup> Normally, STATs are activated upon receptor stimulation by cytokines, growth factors, and other polypeptide ligands. However, constitutive activation of the family member Stat3 is highly prevalent in human tumors.<sup>2,3</sup> Compelling evidence demonstrates that aberrantly active Stat3 induces malignant transformation and tumorigenesis,<sup>3</sup> by serving as a master regulator of tumor-promoting molecular events in cells. Stat3 has therefore become a valid target for anticancer drug design. Presently, there are several efforts to discover and develop novel Stat3 inhibitors for therapeutic application and for probing Stat3-mediated molecular and tumor processes.<sup>1–4</sup>

Protein:protein interactions are a critical molecular event in the induction of signal transduction pathways. During activation, the STAT proteins are recruited via the Src homology (SH) 2 domain to the cognate receptor phosphotyrosine (pTyr) peptide motifs. The binding to membrane-bound receptors represents an initial key step for STAT phosphorylation and activation, bringing the proteins into close proximity to tyrosine kinases for the phosphorylation of the critical tyrosine residue (Y705 for Stat3).<sup>1,3,4</sup> Tyrosine phosphorylated STAT monomers engage in dimerization through

a reciprocal pTyr-SH2 domain interaction, creating transcriptionally active STAT:STAT dimers that in the nucleus regulate gene expression by binding to specific DNA-response elements in the promoters of target genes.<sup>1</sup>


Given its importance in STAT activation and function, the initial pTyr-SH2 domain interaction is one of the targeting sites in many drug discovery programs to identify Stat3 inhibitors as novel anticancer agents. Many diverse dimerization-disrupting small-molecule Stat3 inhibitors have been reported, in some cases with cellular activities and evidence of *in vivo* efficacy.<sup>5–18</sup> While the studies using small-molecule inhibitors and genetic modulators<sup>4,19</sup> provide the proof of concept for the potential therapeutic application of Stat3-inhibitory drugs, no small-molecule Stat3-inhibitory agent has thus far advanced to the clinic.

To expedite the identification of clinically useful Stat3 inhibitors, the leading Stat3 dimerization-disrupting small-molecules were subjected to computational (genetically optimized ligand docking, GOLD) analysis for deriving a 3D quantitative structure activity relationship (QSAR) pharmacophore model to predict optimized Stat3 inhibitors. The crystal structure of

**Received Date:** September 24, 2010

**Accepted Date:** October 19, 2010

**Published on Web Date:** October 25, 2010



**Figure 1.** GOLD docking and quantitative structure-activity relationship studies, and pharmacophore modeling of the binding of Stat3 to small-molecule dimerization inhibitors. (A) Stat3 SH2 domain binding sites and key amino acid residues, (B) Stat3 inhibitors GOLD-docked and overlaid with the Stat3 SH2 domain, (C) Pharmacophore plot identifying the optimal distances for the projection of functionality from the centroid unit, (D) A GOLD docked purine derivative superimposed over the pharmacophore plot and previously docked Stat3 inhibitors, and (E) Low energy GOLD-docked 8aa in the Stat3 SH2 domain (pdb: 1BG1).

the Stat3:Stat3-DNA ternary complex<sup>20</sup> revealed the structural composition and topology of the SH2 domain binding “hot-spot”, identifying three subpockets on the SH2 domain protein surface that are solvent-accessible, labeled A, B and C (Figure 1A). The GOLD analysis<sup>21</sup> of all known Stat3 inhibitors within the Stat3 SH2 domain yielded homologous binding configurations (Figure 1B), with inhibitors consistently occupying at least two of the three main subpockets (Figure 1B). Most notably, all compounds interacted with subpocket A, which hosts the key pTyr705 group, and is broadly composed of the polar residues Lys591, Ser611, Ser613 and Arg609,<sup>22</sup> and were found to engage these residues through predominantly hydrogen bond donor (HBD) or hydrogen bond acceptor (HBA) groups.


In developing our pharmacophore model from known active compounds, we considered only the functional groups pertinent to effective interaction with the three main binding centers. We prepared a simple pharmacophore plot identifying the optimal positioning of functionality crucial for binding to the Stat3-SH2 domain (Figure 1C). The centroid unit, shown as a blue sphere, represents the potential positioning of the scaffold core from which functionality can be optimally appended to access A, B and C. We then considered the 3D pharmacophore, where we would spe-

cify the relative positions of the functional groups in space. Our pharmacophore model describes an essentially planar, hetero-trisubstituted scaffold decorated with optimal recognition elements and confined within the specified pharmacophore plot (Figure 1C). Computational docking studies identified 2,6,9-trisubstituted purine scaffolds as a promising choice of structural skeleton for projecting functionality into the three vertices of the pharmacophore plot (Figure 1D and 1E).

Forty-seven pharmacophore-directed 2,6,9-trisubstituted purine inhibitors were synthesized (Table 1), as previously reported<sup>23,24</sup> and evaluated by surface plasmon resonance (SPR) analysis<sup>16</sup> for their interactions (as analyte) with Stat3 (target). Over one-third showed high affinity binding to Stat3 ( $K_D < 10 \mu\text{M}$ ), including S31-V3-32, S31-V4-01, S31-V3-31, S31-S2-36, S31-S2-30, S31-V2-66 and S31-S2-38 (Table 1, SPR). Details of the QSAR study and the discussion of the SAR are presented in the Supporting Information.


Our study shows that 2,6,9-trisubstituted purine scaffolds interact with Stat3, presumably at the three subpockets on the Stat3 SH2 domain surface (Figures 1A and 1D). The interaction with Stat3 is expected to disrupt Stat3 binding to its cognate pTyr peptide and hence, Stat3:Stat3 dimerization.<sup>6–8,16</sup> Further evaluation of purine-scaffold molecules in *in vitro* Stat3 DNA-binding assay/electrophoretic mobility shift assay (EMSA) analysis, as previously reported,<sup>16</sup> demonstrated that the select agents, S31-V3-29, S31-V3-30, S31-V3-31, S31-V3-32, S31-V3-34, S31-V4-01, and S31-S2-21, which showed good binding affinity for Stat3 (Table 1, SPR), also strongly inhibited Stat3 activity, with  $\text{IC}_{50}$  values of 27–84  $\mu\text{M}$  (Table 1, EMSA). Data from the EMSA analysis did not always show a good correlation to the SPR analysis. We note that although Stat3 dimerization disruptors may exhibit high potency in inhibiting dimerization, the activities in DNA-binding assay/EMSA analysis have generally been weaker.<sup>16</sup> The reasons for this difference may be the presence of significantly large number of protein “targets” in the nuclear extract preparations utilized in the DNA-binding assay and the potential that disrupting preformed Stat3:Stat3 dimers, as in the DNA-binding assay is a more challenging task, as has previously been suggested.<sup>5,6</sup> Immunoblotting analysis showed a moderate to strong inhibition by S31-V3-31, S31-V3-32, S31-V3-34, and S31-V4-01 of constitutive Stat3 phosphorylation in the v-Src transformed mouse fibroblasts (NIH3T3/v-Src) and the human breast cancer line, MDA-MB-231 that harbor aberrant Stat3 activity<sup>3,4</sup> following treatments for 12, 24, or 48 h (Figure 2A(i) and Figure 2A(ii), pY705, lanes 2, 3, 5, 6, 8, 9, 11, 12, 15, and 18, compared to lanes 1, 4, 7, 10, 13, and 16, and data not shown). By contrast, same treatments have no effect on the constitutive levels of phospho-Erk<sup>MAPK</sup> (pErk1/2) or Src (pSrc) (Figure 2A). The inhibition of Stat3 phosphorylation, however, showed different kinetics among the purine compounds studied. Thus, additional time-course study was performed to provide more insight into the effects of the inhibitors. In NIH3T3/v-Src fibroblasts, treatment with S31-V3-31 or S31-V3-32 consistently inhibited Stat3 activity as early as 15–60 min (Figure 2A(iii), right two panels). Data also shows the Stat3 phosphorylation, which was inhibited early, appeared to be temporarily restored during prolonged

Table 1. Structures and Activities of Purine Scaffold Molecules<sup>a</sup>



Entry	Compound	X	Y	*K <sub>D</sub> (μM) (SPR)	#IC <sub>50</sub> (μM) (EMSA)	Entry	Compound	X	Y	*K <sub>D</sub> (μM) (SPR)	#IC <sub>50</sub> (μM) (EMSA)
1	S3I-V2-74 (8aa)			2.2	>100	25	S3I-V3-34 (8bj)			7.9	53.5 ± 3.8
2	S3I-V2-73 (8ab)			38.4	>100	26	S3I-V3-32 (8bl)			1.2	27.2 ± 4.3
3	S3I-V2-72 (8ac)			2.5	>100	27	S3I-S2-49 (8bt)			>50	>100
4	S3I-J1-32 (8ad)			36.4	>100	28	S3I-S3-30 (8bm)			1.8	>100
5	S3I-J1-16 (8ae)			6.4	>100	29	S3I-S2-32 (8bn)			3.1	>100
6	S3I-J1-17 (8af)			6.1	>100	30	S3I-S2-21 (8bo)			>50	79.7 ± 7.4
7	S3I-J1-29 (8ag)			>50	>100	31	S3I-S2-36 (8bu)			0.8	>100
8	S3I-J1-30 (8ah)			>50	>100	32	S3I-S2-30 (8bv)			0.8	>100
9	S3I-J1-53 (8ai)			>50	>100	33	S3I-S2-29 (8bw)			1.3	>100
10	S3I-J1-18 (8aj)			6.0	>100	34	S3I-S2-38 (8bx)			1.0	>100
11	S3I-J1-19 (8ak)			>50	>100	35	S3I-V3-82 (12a)			>50	n/d
12	S3I-J1-20 (8al)			>50	>100	36	S3I-V3-89 (12b)			2.9	>100
13	S3I-S3-32 (8am)			4.2	>100	37	S3I-V3-83 (12c)			>50	>100
14	S3I-V2-83 (8an)			>50	>100	38	S3I-V3-90 (17a)			3.2	>100
15	S3I-V2-82 (8ao)			>50	>100	39	S3I-V4-01 (17b)			1.3	64.4 ± 4.8
16	S3I-V3-26 (8ba)			5.4	>100	40	S3I-V2-70 (7aa)			27.9	>100
17	S3I-V3-27 (8bb)			4.0	>100	41	S3I-V2-67 (7ab)			14.8	>100
18	S3I-V3-30 (8bp)			2.8	83.6 ± 6.1	42	S3I-V2-66 (7ac)			0.9	>100
19	S3I-V3-29 (8bq)			16.7	74.4 ± 5.4	43	S3I-S3-31 (7am)			>50	>100
20	S3I-V3-28 (8bd)			11.2	>100	44	S3I-V2-81 (7an)			>50	>100
21	S3I-V3-31 (8be)			2.3	57.4 ± 3.9	45	S3I-V2-76 (7ao)			>50	>100
22	S3I-V3-33 (8bf)			39.0	>100	46	S3I-S3-41 (7ay)			2.0	>100
23	S3I-V2-54 (8bs)			>50	>100	47	S3I-S3-28 (7bm)			4.1	>100
24	S3I-S2-20 (8bi)			>50	>100						

<sup>a</sup> \*K<sub>D</sub>, affinity determined by SPR; #IC<sub>50</sub>, concentration at which DNA-binding activity is inhibited by 50 %.



**Figure 2.** Immunoprecipitation and immunoblotting analysis for the effects of agents on intracellular Stat3, Erk<sup>M<sup>APK</sup></sup>, Src, and Stat1 activation. Immunoblotting analysis of whole-cell lysates of equal total protein prepared from NIH3T3/v-Src and MDA-MB-231 cells (A) or from EGF-stimulated NIH3T3/hEGFR fibroblasts (B(i)), or of Stat1 immune complexes prepared from EGF-stimulated NIH3T3/hEGFR fibroblasts (B(ii)) treated or untreated with the indicated agents at 40 or 50  $\mu$ M for the indicated times and probing for pY705Stat3, Stat3, pErk1/2, Erk1/2, pSrc, Src, pStat1, Stat1, or pTyr (clone 4G10). Positions of proteins in gel are labeled; control lanes (0), whole-cell lysates from 0.05% DMSO-treated cells. Data are representative of 5–4 independent determinations.

treatment (Figure 2A(iii), NIH3T3/v-Src). Similarly, in the MDA-MB-231 line, Stat3 phosphorylation was consistently inhibited by S31-V3-31 as early as 15–30 min following treatment, with evidence of restoration during treatment for 6 h (Figure 2A(iii), left, top two panels), while inhibition of Stat3 activation by S31-V3-32 was strong at 6 h following treatment (Figure 2A(iii), left, bottom two panels). While data together suggests different kinetics of inhibition of intracellular constitutive Stat3 phosphorylation by purine scaffolds, data shows that, by 48 h following treatment, Stat3 phosphorylation remains low.

Moreover, studies with S31-V3-34 and S31-V4-01 for effects on ligand-stimulated STAT activation showed a selective inhibition of the epidermal growth factor (EGF)-induced Stat3 phosphorylation in mouse fibroblasts overexpressing the human EGF receptor (NIH3T3/hEGFR), as assessed by immunoblotting of whole-cell lysates (Figure 2B(i), pY705-Stat3, lanes 3 and 4, compared to lane 2). The block of ligand-induced Stat3 phosphorylation suggests that purine agents could interact with the inactive Stat3 monomers, presumably the SH2 domain, and thereby occlude Stat3 binding to the EGFR receptor and, hence, block *de novo* Stat3 phosphorylation, as well as blocking Stat3:Stat3 dimerization, as has been previously reported for other SH2 domain-binding Stat3 inhibitors.<sup>6–8</sup> By contrast, there was no effect on the phosphorylation of Erk (pErk1/2) and Src (pSrc) in the same study (Figure 2B(i)). Importantly, similar treatments showed no significant effect on EGF-induced phosphorylation of the STAT family member, Stat1, as assessed by immunoblotting analysis (Figure 2B(i), pStat1) and by way of Stat1 immune complex precipitation, with general pTyr immunoblotting analysis (Figure 2B(ii)). Thus, although purine scaffolds have typically been employed to target the ATP


pocket of aberrant kinases, we speculate that the size of the appendages and the lack of HBA with the agents in the present study will preclude access to the majority of the confined active sites, while conferring high selectivity for the Stat3 SH2 domain. Aberrant Stat3 activity promotes cancer cell growth and survival, and tumor angiogenesis and metastasis.<sup>5–8,12,25</sup> CyQuant cell proliferation assay shows the human prostate (DU145), breast (MDA-MB-231), and pancreatic cancer (Panc-1) lines and the v-Src-transformed mouse fibroblasts (NIH3T3/v-Src) that harbor constitutively active Stat3 are sensitive to select purine-scaffold small-molecules, including S31-V3-30, S31-V3-31, S31-V3-32, S31-V3-34, and S31-V4-01 which decrease malignant cell viability (Figure 3), with IC<sub>50</sub> values of 41–80  $\mu$ M concentrations (Table 2). The viability of normal mouse fibroblasts (NIH3T3) and the murine thymus epithelial stromal cells (TE-71) that do not harbor aberrant Stat3 activity,<sup>16</sup> however, are not affected by agents, with IC<sub>50</sub> values greater than 500  $\mu$ M (Figure 3 and Table 2). Thus, select purine-scaffold small molecules selectively inhibit Stat3 activation in malignant cells, and induce the loss of viability of tumor cells that harbor persistently active Stat3. Altogether, data presented indicate that select purine compounds, including S31-V3-31, S31-V3-32, S31-V3-34 and S31-V4-01, have an effect on Stat3 activity and induce loss of viability of malignant cells that harbor constitutively active Stat3. Although Stat3 activity appears to be temporarily restored following inhibition, the early initial inhibition of aberrant Stat3 activity is sufficient to promote the loss of viability of malignant cells harboring persistently active Stat3.

Herein is presented the application of QSAR to study the binding of Stat3 dimerization inhibitors to the Stat3 SH2 domain and the identification by QSAR pharmacophore

Table 2. Cell Viability Assay

	IC <sub>50</sub> <sup>a</sup> (μM)					
	NIH3T3	TE-71	MDA-MB-231	Panc-1	DU145	NIH3T3/v-Src
S3I-V3-30	420	> 500	147.8 ± 5.1	74.5 ± 8.4	65.1 ± 8.3	62.5 ± 3.4
S3I-V3-31	> 500	> 500	145.2 ± 4.4	175.7 ± 5.3	68.6 ± 1.8	100.2 ± 2.2
S3I-V3-32	> 500	> 500	100.4 ± 3.2	77.7 ± 2.7	80.2 ± 5.1	45.6 ± 3.1
S3I-V3-34	> 500	> 500	66.1 ± 2.1	77.2 ± 1.9	65.3 ± 2.3	41.1 ± 4.6
S3I-V4-01	> 500	> 500	82.4 ± 1.4	197.6 ± 2.1	75.4 ± 3.4	145.6 ± 6.1

<sup>a</sup> IC<sub>50</sub> values: Drug concentration at which 50% of cell viability is inhibited.



**Figure 3.** Purine scaffolds selectively suppress viability of malignant cells that harbor persistently active Stat3. Human breast (MDA-MB-231), pancreatic (Panc-1), and prostate (DU145) cancer cells, the v-Src transformed (NIH3T3/v-Src) fibroblasts or their normal counterparts (NIH3T3), and the murine thymic stromal epithelial cells (TE-71) were treated or not treated with 30–500 μM of the indicated agents for 48 h and assessed for viability using CyQuant cell proliferation kit. Values, mean ± SD of 3 independent experiments each in triplicate.

modeling of purine scaffolds as a novel class of Stat3 inhibitors, and which are the first of their kind. Novel purine-scaffold small-molecules bind to Stat3, presumably the SH2 domain, and selectively inhibit Stat3 activation *in vitro*, thereby suppressing the viability of tumor cells that are dependent on oncogenic Stat3 signaling. Although the present purine-scaffold inhibitors add to the list of Stat3 dimerization

inhibitors,<sup>9,11,12,14,17,18,26,27</sup> they are more attractive, given the existing clinical application of nucleoside analogs.<sup>28,29</sup> The present purine scaffold provides a suitable platform to develop optimized and clinically viable Stat3 inhibitors.

**SUPPORTING INFORMATION AVAILABLE** Information on compound synthesis, chemical data, and the molecular modeling method, detailed results, the experimental procedures for SPR, DNA-binding activity/EMSA, immunoprecipitation and immunoblotting, and Cyquant cell proliferation assays. This material is available free of charge via the Internet at <http://pubs.acs.org>.

#### AUTHOR INFORMATION

**Corresponding Author:** \*P.T.G.: tel, 905-828-5354; fax, 905-569-5425; e-mail, [patrick.gunning@utoronto.ca](mailto:patrick.gunning@utoronto.ca). J.T.: tel, 407-266-7031; fax, 407-384-2062; e-mail, [jturkson@mail.ucf.edu](mailto:jturkson@mail.ucf.edu).

**Author Contributions:** <sup>§</sup> These two authors contributed equally to this work.

**ACKNOWLEDGMENT** This work was supported by the National Cancer Institute Grants CA106439 (J.T.) and CA128865 (J.T.), and by the Leukemia and Lymphoma Society of Canada (P.T.G.) and the University of Toronto (P.T.G.).

#### REFERENCES

- (1) Darnell, J. E., Jr. Transcription factors as targets for cancer therapy. *Nat. Rev. Cancer* **2002**, *2*, 740–749.
- (2) Turkson, J.; Jove, R. STAT proteins: novel molecular targets for cancer drug discovery. *Oncogene* **2000**, *19*, 6613–6626.
- (3) Turkson, J. STAT proteins as novel targets for cancer drug discovery. *Expert Opin. Ther. Targets* **2004**, *8*, 409–422.
- (4) Yue, P.; Turkson, J. Targeting STAT3 in cancer: how successful are we? *Expert Opin. Invest. Drugs* **2009**, *18*, 45–56.
- (5) Turkson, J.; Kim, J. S.; Zhang, S.; Yuan, J.; Huang, M.; Glenn, M.; Haura, E.; Sebt, S.; Hamilton, A. D.; Jove, R. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. *Mol. Cancer Ther.* **2004**, *3*, 261–269.
- (6) Turkson, J.; Ryan, D.; Kim, J. S.; Zhang, Y.; Chen, Z.; Haura, E.; Laudano, A.; Sebt, S.; Hamilton, A. D.; Jove, R. Phosphotyrosyl peptides block Stat3-mediated DNA-binding activity, gene regulation and cell transformation. *J. Biol. Chem.* **2001**, *276*, 45443–45455.
- (7) Siddiquee, K.; Zhang, S.; Guida, W. C.; Blaskovich, M. A.; Greedy, B.; Lawrence, H. R.; Yip, M. L.; Jove, R.; McLaughlin,

- M. M.; Lawrence, N. J.; Sebt, S. M.; Turkson, J. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. *Proc. Natl. Acad. Sci. U.S.A.* **2007**, *104*, 7391–7396.
- (8) Siddiquee, K. A. Z.; Gunning, P. T.; Glenn, M.; Katt, W. P.; Zhang, S.; Schroeck, C.; Sebt, S. M.; Jove, R.; Hamilton, A. D.; Turkson, J. An Oxazole-Based Small-Molecule Stat3 Inhibitor Modulates Stat3 Stability and Processing and Induces Antitumor Cell Effects. *ACS Chem. Biol.* **2007**, *2*, 787–798.
- (9) Chen, J.; Bai, L.; Bernard, D.; Nikolovska-Coleska, Z.; Gomez, C.; Zhang, J.; Yi, H.; Wang, S. Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors. *ACS Med. Chem. Lett.* **2010**, *1*, 85–89.
- (10) Lin, L.; Hutzen, B.; Zuo, M.; Ball, S.; Deangelis, S.; Foust, E.; Pandit, B.; Ihnat, M. A.; Shenoy, S. S.; Kulp, S.; Li, P. K.; Li, C.; Fuchs, J.; Lin, J. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. *Cancer Res.* **2010**, *70*, 2445–2454.
- (11) Bhasin, D.; Cisek, K.; Pandharkar, T.; Regan, N.; Li, C.; Pandit, B.; Lin, J.; Li, P. K. Design, synthesis, and studies of small molecule STAT3 inhibitors. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 391–395.
- (12) Song, H.; Wang, R.; Wang, S.; Lin, J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102*, 4700–4705.
- (13) Schust, J.; Sperl, B.; Hollis, A.; Mayer, T. U.; Berg, T. Static: a small-molecule inhibitor of STAT3 activation and dimerization. *Chem. Biol.* **2006**, *15*, 1235–1242.
- (14) Ren, Z.; Cabell, L. A.; Schaefer, T. S.; McMurray, J. S. Identification of a high-affinity phosphopeptide inhibitor of stat3. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 633–636.
- (15) McMurray, J. S.; Mandal, P. K.; Liao, W. S.; Ren, Z.; Chen, X. Inhibition of Stat3 by cell-permeable peptidomimetic prodrugs targeted to its SH2 domain. *Adv. Exp. Med. Biol.* **2009**, *611*, 545–546.
- (16) Zhang, X.; Yue, P.; Fletcher, S.; Zhao, W.; Gunning, P. T.; Turkson, J. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. *Biochem. Pharmacol.* **2010**, *79*, 1398–1409.
- (17) Gunning, P. T.; Glenn, M. P.; Siddiquee, K. A.; Katt, W. P.; Masson, E.; Sebt, S. M.; Turkson, J.; Hamilton, A. D. Targeting protein-protein interactions: suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders. *ChemBioChem* **2008**, *9*, 2800–2803.
- (18) Gunning, P. T.; Katt, W. P.; Glenn, M.; Siddiquee, K.; Kim, J. S.; Jove, R.; Sebt, S. M.; Turkson, J.; Hamilton, A. D. Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 1875–1878.
- (19) Turkson, J.; Zhang, S.; Palmer, J.; Kay, H.; Stanko, J.; Mora, L. B.; Sebt, S.; Yu, H.; Jove, R. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent anti-tumor activity. *Mol. Cancer Ther.* **2004**, *3*, 1533–1542.
- (20) Becker, S.; Groner, B.; Muller, C. W. Three-dimensional structure of the Stat3beta homodimer bound to DNA. *Nature* **1998**, *394*, 145–151.
- (21) Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. *J. Mol. Biol.* **1997**, *267*, 727–748.
- (22) Fletcher, S.; Turkson, J.; Gunning, P. T. Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. *ChemMedChem* **2008**, *3*, 1159–1168.
- (23) Fletcher, S.; Shahani, V. M.; Gunning, P. T. Facile and efficient access to 2,6,9-tri-substituted purines through sequential N9, N2 Mitsunobu reactions. *Tetrahedron Lett.* **2009**, *50* (29), 4258–4261.
- (24) Fletcher, S.; Shahani, V. M.; Lough, A. J.; Gunning, P. T. *Tetrahedron* **2010**, DOI: 10.1016/j.tet.2010.03.118.
- (25) Turkson, J.; Zhang, S.; Mora, L. B.; Burns, A.; Sebt, S.; Jove, R. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. *J. Biol. Chem.* **2005**, *280*, 32979–32988.
- (26) Coleman, D. R.; Ren, Z.; Mandal, P. K.; Cameron, A. G.; Dyer, G. A.; Muranjan, S.; Campbell, M.; Chen, X.; McMurray, J. S. Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor. *J. Med. Chem.* **2005**, *48*, 6661–6670.
- (27) Mandal, P. K.; Limbrick, D.; Coleman, D. R.; Dyer, G. A.; Ren, Z.; Birtwistle, J. S.; Xiong, C.; Chen, X.; Briggs, J. M.; McMurray, J. S. Conformationally constrained peptidomimetic inhibitors of signal transducer and activator of transcription 3: evaluation and molecular modeling. *J. Med. Chem.* **2009**, *52*, 2429–2442.
- (28) Galmarini, C. M.; Mackey, J. R.; Dumontet, C. Nucleoside analogues and nucleobases in cancer treatment. *Lancet Oncol.* **2002**, *3*, 415–424.
- (29) Parker, W. B.; Secrist, J. A., 3rd; Waud, W. R. Purine nucleoside antimetabolites in development for the treatment of cancer. *Curr. Opin. Invest. Drugs* **2004**, *5*, 592–596.